Viatris Management

Management Kriterienprüfungen 1/4

Viatris' CEO ist Scott Smith , ernannt in Apr 2023, hat eine Amtszeit von 1.17 Jahren. Die jährliche Gesamtvergütung beträgt $16.27M , bestehend aus 6.3% Gehalt und 93.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.007% der Aktien des Unternehmens, im Wert von $863.11K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.8 Jahre bzw. 4 Jahre.

Wichtige Informationen

Scott Smith

Geschäftsführender

US$16.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.3%
Amtszeit als Geschäftsführer	1.4yrs
Eigentum des Geschäftsführers	0.007%
Durchschnittliche Amtszeit des Managements	1.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Scott Smith im Vergleich zu den Einnahmen von Viatris verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$646m
Mar 31 2024	n/a	n/a	-US$56m
Dec 31 2023	US$16m	US$1m	US$55m

Vergütung im Vergleich zum Markt: ScottDie Gesamtvergütung ($USD16.27M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.82M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Scott mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Scott Smith (62 yo)

1.4yrs

Amtszeit

US$16,271,094

Vergütung

Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Scott Smith	CEO & Director	1.4yrs	US$16.27m	0.0072% $ 985.6k
Brian Roman	Chief Legal Officer	7.2yrs	US$4.11m	0.0057% $ 781.6k
Theodora Mistras	Chief Financial Officer	less than a year	keine Daten	keine Daten
Paul Campbell	Chief Accounting Officer	9.3yrs	keine Daten	0.013% $ 1.8m
Ramkumar Rayapureddy	Chief Information Officer	less than a year	keine Daten	keine Daten
Andrew Enrietti	Chief People Officer	3.7yrs	keine Daten	keine Daten
Menassie Taddese	President of Emerging Markets	no data	keine Daten	keine Daten
Derek Glover	Chief Quality Officer	no data	keine Daten	keine Daten
Lara Ramsburg	Chief Corporate Affairs Officer	no data	keine Daten	keine Daten
Jeffrey Nau	President of Viatris Eye Care Division	no data	keine Daten	keine Daten
Philippe Martin	Chief R&D Officer	less than a year	keine Daten	keine Daten
Corinne Le Goff	Chief Commercial Officer	less than a year	keine Daten	keine Daten

1.1yrs

Durchschnittliche Betriebszugehörigkeit

53.5yo

Durchschnittliches Alter

Erfahrenes Management: 0A5VDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Scott Smith	CEO & Director	1.8yrs	US$16.27m	0.0072% $ 985.6k
JoEllen Dillon	Independent Non-Executive Director	10.4yrs	US$200.00k	0.0049% $ 678.2k
Wyllie Cornwell	Independent Director	3.8yrs	US$170.00k	0.0051% $ 708.6k
Elisha Finney	Independent Director	1.8yrs	US$170.00k	0.0016% $ 217.8k
James Kilts	Independent Director	3.8yrs	US$170.00k	0.0098% $ 1.4m
Harry Korman	Independent Non-Executive Director	6.3yrs	US$175.00k	0.0075% $ 1.0m
Melina Higgins	Independent Non-Executive Chairman	11.6yrs	US$254.38k	0.015% $ 2.0m
Robert Coury	Chairman Emeritus & Senior Strategic Advisor	less than a year	US$41.50m	0.053% $ 7.3m
Mark Parrish	Independent Vice Chairman & Lead Independent Director	15yrs	US$250.00k	0.010% $ 1.4m
Rajiv Malik	Director	12.7yrs	US$12.48m	0.042% $ 5.8m
Richard Mark	Independent Non-Executive Director	4.7yrs	US$220.00k	0.0061% $ 835.4k
Leo Groothuis	Independent Director	1.3yrs	US$113.54k	0.0019% $ 256.4k

4.3yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: 0A5VDie Vorstandsmitglieder gelten als erfahren (4 Jahre durchschnittliche Amtszeit).

Viatris Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Director recently sold US$3.6m worth of stock

Chief Legal Officer recently sold US$928k worth of stock

President of Developed Markets recently sold US$3.0m worth of stock

Viatris Announces CFO Changes

Recent updates

Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

Second quarter dividend of US$0.12 announced

Second quarter 2024 earnings released: US$0.27 loss per share (vs US$0.22 profit in 2Q 2023)

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024

Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS).

Director recently sold US$3.6m worth of stock

Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Chief Legal Officer recently sold US$928k worth of stock

First quarter dividend of US$0.12 announced

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings released: EPS: US$0.095 (vs US$0.19 in 1Q 2023)

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

Fourth quarter dividend of US$0.12 announced

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Full year 2023 earnings released: EPS: US$0.046 (vs US$1.72 in FY 2022)

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.29 in 3Q 2022)

Viatris Inc., Annual General Meeting, Dec 15, 2023

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Now 23% undervalued after recent price drop

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Now 23% undervalued

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings released: EPS: US$0.22 (vs US$0.26 in 2Q 2022)

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.33 in 1Q 2022)

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

Full year 2022 earnings released: EPS: US$1.72 (vs US$1.05 loss in FY 2021)

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.26 in 3Q 2021)

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Independent Non-Executive Director recently sold US$100k worth of stock

Upcoming dividend of US$0.12 per share

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.23 loss in 2Q 2021)

Viatris Inc. to Report Q2, 2022 Results on Aug 08, 2022